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Synopsis		The	International	Ocular	Syphilis	Study	Group	reports	that	syphilitic	uveitis	is	most	often	posterior,	associated	with	secondary	syphilis,	diagnosed	serologically	and	treated	with	penicillin.	Serologic	testing	of	all	patients	with	uveitis	ensures	timely	identification.	
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Abstract			Background:	Syphilitic	uveitis	is	re-emerging	alongside	the	systemic	infection.	In	July	2017,	an	international	group	of	uveitis-specialized	ophthalmologists	formed	the	International	Ocular	Syphilis	Study	Group	to	define	current	practice	patterns.	Methods:	103	Study	Group	members	based	in	34	countries	completed	a	25-item	questionnaire	focused	on	caseload,	clinical	presentations,	use	and	interpretation	of	investigations,	treatment,	and	clinical	indicators	of	poor	prognosis.	Results:	Members	managed	a	mean	of	6.1	patients	with	syphilitic	uveitis	in	clinics	that	averaged	707	annual	cases	of	uveitis	(0.9%);	%);	53.2%	reported	increasing	numbers	over	the	past	decade.	Patients	presented	to	more	members	(40.2%)	during	secondary	syphilis.	Uveitis	was	usually	posterior	(60.8%)	or	pan	(22.5%);	complications	included	optic	neuropathy,	macular	oedema,	and	posterior	synechiae.	All	members	diagnosed	syphilitic	uveitis	using	serologic	tests	(simultaneous	or	sequential	testing	algorithms),	and	97.0%	routinely	checked	for	HIV	co-infection.	Cerebrospinal	fluid	analysis	was	ordered	by	90.2%	of	members,	and	92.7%	took	uveitis	plus	VDRL	or	FTA-ABS	to	indicate	neurosyphilis.	Patients	were	commonly	co-managed	with	infectious	disease	physicians,	and	treated	with	penicillin	for	at	least	10	to	14	days,	plus	corticosteroid.	Features	predicting	poor	outcome	included	optic	neuropathy	(86.3%)	and	initial	misdiagnosis	(63.7%).	Reasons	for	delayed	diagnosis	were	often	practitioner-related.	82.5%	of	members	tested	every	patient	they	managed	with	uveitis	for	syphilis.	Conclusion:	This	comprehensive	report	by	an	international	group	of	uveitis-specialized	ophthalmologists	provides	a	current	approach	for	the	management	of	syphilitic	uveitis.	
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Introduction		The	latest	analysis	by	the	World	Health	Organization	(WHO)	demonstrates	that	the	prevalence	and	incidence	of	syphilis	continue	to	be	high	worldwide.	Based	on	data	collected	between	2005	and	2012,	regional	prevalence	varies	between	0.2%	and	1.8%	and	regional	incidence	varies	between	0.9	and	4.4	cases	per	1,000	persons	(women	or	men);	corresponding	pooled	global	figures	are	0.5%	and	1.5	cases	per	1,000	persons	(women	or	men)	respectively.1	Syphilis	prevalence	and	incidence	remain	highest	in	the	African	region,	but	have	been	rising	in	high	income	countries	since	approximately	2000.	One	comprehensive	review	shows	a	significant	increase	in	the	syphilis	notification	rates	in	23	of	27	high-income	countries	across	North	America,	Europe	and	the	Asia-Pacific	Region,	and	highlights	that	this	increase	is	due	primarily	to	an	increasing	number	of	infections	among	men	who	have	sex	with	men	(MSM).2			An	uncommon,	but	serious	manifestation	of	syphilis	is	uveitis	(or	inflammation	inside	the	eye).3	Surveillance	data	have	provided	an	estimated	risk	of	“ocular	syphilis”	–	almost	always	presenting	as	uveitis	–	as	just	0.6%	to	2.7%	of	total	infections.4-6	However,	the	vision	is	frequently	impacted	in	this	condition:	in	the	largest	series	published	to	date,	including	85	persons	from	The	Netherlands,	58.8%	presented	with	reduction	in	vision	to	a	level	that	typically	limits	driving	(Snellen	visual	acuity	<	6/12)	and	29.4%	suffered	blindness	(Snellen	visual	acuity	<	6/60).7	Current	studies	from	the	United	States,6,8	Western	Europe9,10	and	Brazil11	suggest	syphilitic	uveitis	is	increasing	in	prevalence	and	incidence,	in	parallel	with	the	systemic	infection.			
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Consistent	with	increasing	numbers	of	individuals	suffering	from	syphilitic	uveitis,	multiple	articles	are	presently	being	published	about	cohorts	of	patients	with	the	condition.	In	the	last	5	years	alone,	multiple	independent	studies	from	countries	in	the	Americas,	Western	Europe	and	Australasia	have	reported	on	different	clinical	subjects	relating	to	this	form	of	uveitis,	including	regional	epidemiology,	ophthalmic	features,	ocular	and	systemic	diagnostics,	anti-microbial	drug	and	corticosteroid	treatments,	and	prognosis.5,7,9,11-23	Recently	a	group	of	103	clinicians,	specializing	in	the	management	of	uveitis	and	based	in	34	nations,	came	together	as	the	International	Ocular	Syphilis	Study	Group	to	provide	a	global	perspective	of	current	practice	patterns	for	syphilitic	uveitis.	This	article	presents	the	collective	experience	of	this	group	on	clinical	presentations	and	outcomes,	as	well	as	the	preferred	approach	to	investigation	and	treatment.	
	
Materials	and	Methods	
	In	July	2017,	a	subset	of	the	membership	of	the	International	Ocular	Inflammation	Society	(IOIS)	formed	the	International	Ocular	Syphilis	Study	Group.	The	IOIS	is	a	global	scientific	society,	which	is	dedicated	to	the	study	of	inflammatory	eye	diseases.	At	the	time	of	this	project,	the	IOIS	membership	totalled	268	clinicians	and	scientists:	103	clinical	members	joined	the	Study	Group,	which	aimed	to	establish	current	practice	patterns	in	the	management	of	syphilitic	uveitis.	These	members	were	based	in	the	following	34	countries:	Argentina,	Australia,	Austria,	Belgium,	Brazil,	Canada,	Chile,	Denmark,	Egypt,	France,	Germany,	Greece,	India,	Indonesia,	Italy,	Japan,	Malaysia,	Mexico,	Norway,	Peru,	Poland,	Portugal,	Singapore,	South	Africa,	Spain,	Switzerland,	Taiwan,	Thailand,	the	Netherlands,	Tunisia,	Turkey,	the	United	Kingdom,	the	United	Arab	Emirates	and	the	United	States.	All	Study	Group	members	completed	a	25-question	
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survey	that	was	formulated	by	GO,	JMF,	TEA,	PJM	and	JRS,	using	online	survey	software	(surveymonkey.com).	Members	reported	on:	case	load	and	routes	of	referral;	clinical	presentations,	including	stage	of	syphilis,	uveitis	subtype	and	ophthalmic	complications;	use	of	investigations,	including	serological	studies,	examination	of	cerebrospinal	fluid	(CSF)	and	testing	for	human	immunodeficiency	virus	(HIV);	interpretation	of	uveitis	as	a	manifestation	of	neurosyphilis;	treatment,	including	choice	and	duration	of	antibiotic,	and	adjunctive	corticosteroid	therapy;	clinical	indicators	of	poor	prognosis,	and	standard	follow-up	policy.	The	survey	questions	are	provided	in	Supplementary	Table	1.		
	
Results		Members	of	the	International	Ocular	Syphilis	Study	Group	reported	their	recent	clinical	load	of	syphilitic	uveitis.	In	2016,	97	of	103	members	(94.2%)	managed	a	mean	of	6.1	patients	with	syphilitic	uveitis	in	clinical	practices	that	averaged	707	total	annual	cases	of	uveitis.	Considering	only	those	42	members	with	high	volume	clinical	practices	that	involved	consultations	with	at	least	500	patients	with	uveitis	per	year,	the	mean	number	of	patients	with	syphilitic	uveitis	managed	in	2016	was	10.0,	with	total	annual	cases	of	uveitis	averaging	1350.	Amongst	79	members	who	were	able	to	compare	numbers	of	cases	managed	over	the	prior	decade,	42	(53.2%)	reported	they	had	observed	an	increase	in	the	number,	29	(36.7%)	reported	no	change	in	number,	and	8	(10.1%)	reported	a	decrease	in	number.			For	73.8%	of	Study	Group	members	(n	=	76	of	103),	the	most	frequent	referral	of	a	patient	with	syphilitic	uveitis	was	from	a	fellow	ophthalmologist	who	had	identified	uveitis,	but	not	determined	the	cause.	Some	members	reported	other	frequent	routes	for	
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their	referrals,	including:	from	another	ophthalmologist	with	the	diagnosis	of	syphilitic	uveitis	(n	=	3,	2.9%);	from	a	non-ophthalmologist	health	practitioner	with	the	diagnosis	of	syphilis	(n	=	2,	1.9%);	and	HIV-positive	individuals	requesting	ophthalmic	screening	(n	=	7,	6.8%).	Patients	with	uveitis	most	commonly	presented	to	Study	Group	members	(n	=	102)	during	the	secondary	stage	of	syphilis	(n	=	41,	40.2%),	followed	by	latent	and	tertiary	stages	(n	=	23,	22.6%	and	n	=	26,	25.5%,	respectively),	and	the	primary	stage	(n	=	3,	2.9%).	Following	the	Standardization	of	Uveitis	Nomenclature	anatomic	classification,24	102	members	reported	the	form	of	syphilitic	uveitis	they	managed	most	frequently	was	posterior	or	pan-	uveitis	(n	=	62,	60.8%	or	n	=	23,	22.5%,	respectively),	while	anterior	and	intermediate	uveitis	were	less	often	identified	as	the	most	frequently	treated	form	(n	=	4,	3.9%	and	n	=	2,	2.0%,	respectively).	Study	Group	members	encountered	multiple	ocular	complications	in	their	practices	of	syphilitic	uveitis,	including	most	commonly,	optic	neuropathy	(n	=	69	of	100	members,	68.3%),	cystoid	macular	oedema	(n	=	51,	50.5%)	and	posterior	synechiae	(n	=	51,	50.5%).	Routes	of	referral	and	clinical	presentations	of	syphilitic	uveitis	are	presented	in	Table	1.		 	
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Table	1.	Referral	patterns	and	clinical	presentations	to	uveitis-specialised	ophthalmologists	in	patients	with	syphilitic	uveitis	(n	=	103	International	Ocular	Syphilis	Study	Group	members	responding,	unless	otherwise	stated).	
	
Clinical	Variable	
	
Number	(%)	Most	common	route	for	referral			
• Referred	by	ophthalmologist	with	diagnosis	of	uveitis	
• Referred	by	ophthalmologist	with	diagnosis	of	syphilitic	uveitis	
• Referred	by	non-ophthalmologist	with	diagnosis	of	syphilis	
• HIV-positive	patients	referred	for	ophthalmic	screening	
• No	common	route		
	76	(73.8)		3	(2.9)	2	(1.9)	7	(6.8)	15	(14.6)		Most	frequent	stage	of	syphilis*		(n=102	members	responding)	
• Primary	
• Secondary	
• Latent	
• Tertiary		
• No	difference	in	frequency	
		3	(2.9)	41	(40.2)	23	(22.6)	26	(25.5)	9	(8.8)		Most	frequent	form	of	uveitis*	(n=102	members	responding)		
• Anterior	uveitis	
• Intermediate	uveitis	
• Posterior	uveitis	
• Panuveitis	
• No	difference	in	frequency	
		4	(3.9)	2	(2.0)	62	(60.8)	23	(22.5)	11	(10.8)		Ocular	complications	of	syphilitic	uveitis*		(n=101	members	responding)	
• Optic	neuropathy	
• Cystoid	macular	oedema	
• Posterior	synechiae	
• Cataract	
• Retinal	vascular	occlusion		
• Epiretinal	membrane	
• Ocular	hypertension/glaucoma	
• Retinal	detachment	
• Retinal	neovascularization	
• Hypotony	
• Choroidal	neovascularization	
		69	(68.3)	51	(50.5)	51	(50.5)	42	(41.6)	36	(35.6)	25	(24.8)	22	(21.8)	15	(14.9)	15	(14.9)	5	(5.0)	4	(4.0)				 	
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All	103	Study	Group	members	relied	on	serologic	testing	to	make	a	diagnosis	of	syphilitic	uveitis.	A	majority	of	members	(n	=	62,	60.2%)	requested	non-treponemal	and	treponemal	tests	simultaneously.	However,	a	substantial	number	(n	=	41,	39.8%)	preferred	a	sequential	testing	algorithm,	with	approximately	one-half	of	these	practitioners	using	the	traditional	algorithm	and	the	remainder	using	the	reverse	algorithm.	Eleven	members	(10.7%)	had	also	employed	polymerase	chain	reaction	(PCR)	to	detect	Treponema	pallidum	in	ocular	fluid.	Lumbar	puncture	and	analysis	of	CSF	were	ordered	routinely	or	for	specific	indications	by	42	(40.8%)	and	51	(49.5%)	Study	Group	members,	respectively;	common	indications	included	optic	nerve	involvement	and	HIV	positivity.	Amongst	the	members	who	provided	their	criteria	for	diagnosis	of	neurosyphilis	in	a	patient	with	syphilitic	uveitis,	89	of	96	(92.7%)	judged	the	presence	of	ocular	inflammation	plus	positive	CSF	VDRL	or	FTA-ABS	to	establish	this	condition.	Smaller	numbers	agreed	that	lesser	evidence	indicated	neurosyphilis,	including	46	of	88	(52.3%)	accepting	uveitis	plus	an	abnormal	CSF	cell	count	or	protein	level,	and	33	of	91	(36.3%)	accepting	uveitis	alone	as	sufficient	for	the	diagnosis.	Serologic	testing	for	HIV	infection	was	recommended	in	all	patients	presenting	with	syphilitic	uveitis	by	98	of	101	(97.0%),	and	if	a	first	test	for	HIV	was	negative,	33.7%	of	the	group	(n	=	34	of	101)	repeated	the	test	3	months	later.	Approach	and	interpretation	of	investigations	in	the	patient	with	syphilitic	uveitis	are	summarized	in	Table	2.		 	
	 10	
Table	2.	Approach	and	interpretation	of	investigations	in	patients	with	syphilitic	uveitis	(n	=	103	International	Ocular	Syphilis	Study	Group	members	responding,	unless	otherwise	stated).	
	
Clinical	Variable	
	
Number	(%)	Serologic	testing	for	syphilis		
• Performed	
• Traditional	testing	algorithm	(initial	non-treponemal	test	followed	by	treponemal	test)	
• Reverse	testing	algorithm	(initial	treponemal	test	followed	by	non-treponemal	test)	
• Simultaneous	treponemal	and	non-treponemal	tests	
	103	(100%)		21	(20.4)		20	(19.4)	62	(60.2)		
T.	pallidum	PCR	on	ocular	fluid		
• Performed	 	11	(10.7)		CSF	examination	
• Routinely	performed	
• Sometimes	performed	
• Patients	with	optic	nerve	involvement	
• HIV-positive	patients	
• Other	situations*	
• Not	performed	
	42	(40.8)	51	(49.5)						36	(70.6)						25	(49.0)						22	(43.1)	10	(9.7)		Criteria	for	diagnosis	of	neurosyphilis	
• Presence	of	intraocular	inflammation	+	positive	CSF	VDRL	or	FTA-ABS	(n=96	members	responding)	
• Presence	of	intraocular	inflammation	+	abnormal	CSF	cell	count	or	protein	level,	but	negative	CSF	VDRL	or	FTA-ABS	(n=88	members	responding)	
• Presence	of	intraocular	inflammation	alone	(n=91	members	responding)	
		89	(92.7)				46	(52.3)		33	(36.3)		Serologic	testing	for	HIV	(n=101	members	responding)	
• Routinely	performed	
• Sometimes	performed	
• Not	performed	
		98	(97.0)	3	(3.0)	0	(0.0)		Repeated	(at	3	months)	serologic	testing	for	HIV	if	first	test	negative		(n=101	members	responding)	
• Performed	 		34	(33.7)		Abbreviations:	PCR	=	polymerase	chain	reaction,	CSF	=	cerebrospinal	fluid,	HIV	=	human	immunodeficiency	virus		*Other	situations	included:	recommendation	by	co-managing	internist;	posterior	eye	involvement;	neurological	symptoms;	and	cost.		 	
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A	majority	of	Study	Group	members	(n	=	64	of	103,	62.1%)	referred	patients	with	syphilitic	uveitis	to	an	infectious	disease	physician	for	antibiotic	treatment,	although	some	ophthalmologists	(n	=	25,	24.3%)	prescribed	these	drugs	themselves	based	on	their	own	expertise	or	the	advice	of	an	infectious	disease	specialist.	Most	members	treated	their	patients	with	different	forms	of	penicillin,	including	intravenous	aqueous	crystalline	penicillin	G	(n	=	63,	61.8%),	and	intramuscular	benzathine	penicillin	G	(n	=	25,	24.5%)	and	procaine	penicillin	G	(n	=	2,	2.0%).	A	small	number	preferred	to	treat	with	other	antibiotics,	including	intravenous	ceftriaxone	(n	=	7,	6.9%)	and	oral	doxycycline	(n	=	1,	1.0%).	Treatment	was	almost	always	continued	for	10	to	14	days	or	longer	(n	=	63,	66.3%	and	28,	29.5%	of	95	members,	respectively).	Of	102	members,	32	(31.4%)	routinely	prescribed	adjunctive	corticosteroid	therapy,	and	68	(66.7%)	prescribed	this	therapy	for	selected	patients.	Corticosteroids	were	given	topically	(n	=70	of	100	members,	70.0%),	by	local	injection	(n	=	16,	16.0%)	and/or	systemically	(n	=	82,	82.0%).	When	adjunctive	systemic	corticosteroid	therapy	was	used,	this	was	most	often	initiated	during,	but	after	the	start	of	antibiotics	(n	=	45	of	82	members,	54.9%).	However,	14	members	(17.1%)	started	the	corticosteroid	at	the	same	time	as	the	antibiotic;	4	members	(4.9%)	started	the	corticosteroid	after	the	course	of	antibiotic;	and	19	members	(23.1%)	adjusted	the	timing	of	corticosteroid	treatment	depending	on	the	clinical	situation.	The	treatment	of	syphilitic	uveitis	is	described	in	Table	3.		 	
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Table	3.	Treatment	of	patients	with	syphilitic	uveitis	(n	=	103	International	Ocular	Syphilis	Study	Group	members	responding,	unless	otherwise	stated).	
	
Clinical	Variable	
	
Number	(%)	Approach	to	antibiotic	treatment	of	syphilis		
• Prescribe	antibiotics	based	on	own	expertise	
• Prescribe	antibiotics	as	advised	by	an	infectious	disease	physician	
• Refer	patient	to	infectious	disease	physician	for	treatment	
• Other	approaches	to	antibiotic	treatment	
	12	(11.7)	13	(12.6)	64	(62.1)	14	(13.6)		
	Preferred	antibiotic	(n=102	members	responding)	
• Aqueous	penicillin	G	(intravenous)	
• Penicillin	G	benzathine	(intramuscular)	
• Ceftriaxone	(intravenous)	
• Procaine	penicillin	G	(intramuscular)	plus	probenecid	(oral)	
• Doxycycline	(oral)	
• Tetracycline	(oral)	
• Combinations	of	or	different	antibiotics	
		63	(61.8)	25	(24.5)	7	(6.9)	2	(2.0)	1	(1.0)	0	(0.0)	4	(3.9)	
	Duration	of	antibiotic	treatment	(in	days)		(n=95	members	responding)	
• Less	than	10	
• 10-14		
• 14-21	More	than	21	
		4	(4.2)	63	(66.3)	19	(20.0)	9	(9.5)		Adjunctive	corticosteroid	therapy	(n=102	members	responding)	
• Routinely	prescribed	
• Sometimes	prescribed		
• Not	prescribed	
		32	(31.4)	68	(66.7)	2	(1.9)	
	Administration	of	corticosteroid	(n=100	members	responding)	
• Topically	applied	(eye	drops)	
• Locally	injected	
• Systemic	
• Initiated	with	antibiotic	treatment		
• Initiated	during	but	after	start	of	antibiotic	treatment	
• Initiated	after	antibiotic	treatment	completed	
• No	standard	timing	of	administration	
		70	(70.0)	16	(16.0)	82	(82.0)						14	(17.1)						45	(54.9)						4	(4.9)						19	(23.1)		
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In	the	clinical	practices	of	most	Study	Group	members	(n	=	74	of	103,	71.9%),	all	patients	with	syphilitic	uveitis	received	long-term	follow-up	after	resolution	of	the	inflammation;	some	members	(n	=	26,	25.2%)	selected	patients	for	follow-up	based	on	presence	of	ocular	complications,	HIV	positive	status	and	risk	factors	for	re-infection	with	T.	pallidum.	Study	Group	members	agreed	that	multiple	factors	predicted	poor	visual	outcome	in	syphilitic	uveitis,	including	optic	neuropathy	(n	=	88	of	102	members,	86.3%),	initial	misdiagnosis	(n	=	65,	63.7%),	HIV	co-infection	(n	=	40,	39.2%),	retinal	involvement	(n	=	41,	40.2%)	and	bilateral	disease	(n	=	21,	20.6%).	Reasons	cited	by	Study	Members	for	a	delay	in	the	diagnosis	of	syphilis	were	often	practitioner-related,	including	not	ordering	serologic	tests	(n	=	27,	29.7%),	lack	of	medical	knowledge	or	suspicion	of	syphilis	(n	=	27,	29.7%),	and	initial	misdiagnosis	(n	=	19,	20.9%).	Eighty-five	of	103	members	(82.5%)	performed	syphilis	testing	in	every	patient	who	presented	to	them	with	uveitis.	The	approach	to	follow-up	and	prediction	of	the	outcome	of	syphilitic	uveitis	are	presented	in	Table	4.		 	
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Table	4.	Approach	to	follow-up	and	prediction	of	outcome	for	patients	with	syphilitic	uveitis	by	uveitis-specialised	ophthalmologists	(n	=	103	International	Ocular	Syphilis	Study	Group	members	responding,	unless	otherwise	stated).	
	
Clinical	Variable	
	
Number	(%)	Patients	followed	after	resolution	of	uveitis	
• All	patients	
• Some	patients	
• Patients	with	ocular	complications	
• HIV-positive	patients	
• Patients	judged	at	high	risk	of	re-infection	with	T.	pallidum	
• No	patients	
	74	(71.9)	26	(25.2)						26	(100)						17	(65.4)						9	(34.6)		3	(2.9)		Features	predictive	of	poor	visual	outcome		(n=102	members	responding)	
• Optic	neuropathy	
• Initial	misdiagnosis	
• HIV-positive	patient	
• Retinal	involvement	
• Bilateral	disease	
		88	(86.3)	65	(63.7)	40	(39.2)	41	(40.2)	21	(20.6)		Factors	delaying	the	diagnosis	of	syphilis		(n=91	members	responding)	
• Serology	not	ordered		
• Lack	of	medical	knowledge	or	suspicion	for	syphilis		
• Initial	misdiagnosis		
• Variable	clinical	presentations		
• Limited	access	to	appropriate	medical	care		
• Poor	compliance		
• Delayed	presentation	
• False	negative	serology	
• Inappropriate	initial	treatment	
		27	(29.7)	27	(29.7)	19	(20.9)	16	(17.6)	14	(15.4)	13	(14.3)	9	(9.9)	7	(7.7)	7	(7.7)		Abbreviation:	HIV	=	human	immunodeficiency	virus	
	 	
	 15	
Discussion	
	Syphilitic	uveitis	is	re-emerging	internationally,	in	parallel	with	the	increasing	incidence	of	the	systemic	infectious	disease.6,8,25	We	present	a	description	of	current	practice	patterns	by	collating	the	experience	of	a	group	of	103	clinicians	–	members	of	the	International	Ocular	Syphilis	Study	Group	–	who	specialize	in	the	management	of	uveitis,	and	evaluate	an	average	of	approximately	700	cases	of	uveitis	annually.	In	keeping	with	recently	published,	detailed	surveys	of	individual	practices,25-27	the	number	of	cases	of	uveitis	caused	by	ocular	syphilis	is	less	than	1%	of	the	total	case	load,	but	just	over	one-half	of	Study	Group	members	have	observed	an	increase	in	the	number	of	cases	of	syphilitic	uveitis	over	the	past	decade.	Members	of	the	Study	Group	most	commonly	encounter	uveitis	in	the	setting	of	secondary	syphilis,	but	also	during	latent	and	tertiary	syphilis,	and	occasionally	during	primary	syphilis.	For	approximately	85%	of	members,	these	patients	present	most	frequently	with	posterior	uveitis	or	panuveitis.	Complications	of	syphilitic	uveitis	are	protean,	affecting	both	anterior	and	posterior	eye,	and	visually	significant.	In	particular,	cystoid	macular	oedema	and	optic	neuropathy,	identified	by	one-half	and	two-thirds	of	members,	respectively,	are	well-established	causes	of	vision	loss	that	may	be	irreversible	in	patients	with	uveitis.28		Study	Group	members	rely	on	serologic	testing	to	diagnose	syphilis	as	the	cause	of	uveitis;	analysis	of	intraocular	samples	by	PCR	is	seldom	utilized.	A	diagnostic	approach	that	has	been	promoted	by	uveitis	specialists	for	several	decades	involves	simultaneous	testing	for	non-treponemal	and	treponemal	antigens,	rather	than	the	traditional	algorithm	of	a	non-treponemal	test,	followed	by	treponemal	test	if	the	former	is	positive.29	This	approach	has	been	taken	to	avoid	falsely	negative	non-treponemal	tests,	
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particularly	early	or	late	in	the	course	of	the	infection,	when	uveitis	may	first	present.	Following	recent	introduction	of	automated,	low-cost	treponemal	immunoassays,	many	diagnostic	laboratories	are	adopting	a	reverse	testing	algorithm,	i.e.,	treponemal	test	followed	by	non-treponemal	test,	when	the	former	is	positive.30	Thus,	while	approximately	60%	of	Study	Group	members	continue	to	follow	the	simultaneous	testing	model,	20%	have	moved	to	the	reverse	testing	algorithm.	In	addition	to	serologic	testing,	most	members	order	CSF	analysis	in	patients	with	uveitis	secondary	to	syphilis.	Over	90%	of	members	follow	the	recommendation	of	the	United	States	Centers	for	Disease	Control	and	Prevention	(CDC)	when	diagnosing	neurosyphilis,	requiring	the	presence	of	intraocular	inflammation,	plus	positive	CSF	VDRL	and/or	FTA-ABS,31	but	one-third	of	members	also	consider	uveitis	alone	to	indicate	neurosyphilis.	There	is	a	strong	association	between	HIV	infection	and	syphilis,	which	is	believed	to	reflect	multiple	factors,	including	common	sexual	transmission,	and	modulatory	effects	of	HIV	and	highly	active	anti-retroviral	therapy	on	the	immune	system.32	Accordingly,	97%	of	Study	Group	members	order	serologic	testing	for	HIV	in	any	patient	who	is	diagnosed	with	syphilitic	uveitis.						The	CDC	recommends	ocular	syphilis	be	managed	according	to	their	guidelines	for	neurosyphilis.31	That	recommendation	is	10	to	14	days	of	treatment	with	intravenous	aqueous	penicillin	G,	intramuscular	procaine	penicillin	G	(with	oral	probenecid)	or,	in	the	case	of	penicillin	allergy,	intravenous	ceftriaxone.	A	majority	of	Study	Group	members	liaise	with	an	infectious	disease	physician	to	treat	their	patients	and	follow	this	medical	approach.	Addition	of	corticosteroid	has	been	suggested	to	avoid	a	Jarisch-Herxheimer	reaction,	which	is	the	inflammatory	response	that	often	accompanies	initiation	of	antimicrobial	treatment	in	syphilis33	and	may	exacerbate	uveitis.34	Almost	
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all	Study	Group	members	prescribe	adjunctive	corticosteroid,	which	typically	is	delivered	systemically	or	in	the	form	of	eye	drops.	The	preference	for	these	delivery	routes	is	consistent	with	the	difficulty	of	removing	locally	injected	corticosteroid	in	the	event	of	a	complication,	and	with	the	recent	report	of	delayed	resolution	of	syphilitic	uveitis	in	patients	who	receive	local	corticosteroid	injections.19			Syphilitic	uveitis	causes	long-term	visual	disability	in	a	significant	number	of	persons:	among	one	cohort	of	patients	with	ocular	syphilis,	who	were	treated	and	followed	at	Johns	Hopkins	School	of	Medicine,	and	described	in	detail,	one	in	5	eyes	lost	visual	acuity	to	a	level	below	20/40,	which	prohibits	driving	in	many	countries.14	Thus,	a	valuable	output	of	our	work	was	the	collation	of	poor	prognostic	factors	based	on	the	expertise	of	Study	Group	members.	Multiple	factors	were	considered	predictive	of	poor	visual	prognosis,	including	initial	misdiagnosis,	HIV	co-infection,	posterior	eye	involvement,	bilateral	disease	and	the	complication	of	optic	neuropathy.	Delayed	diagnosis	and	treatment	have	been	associated	with	a	relatively	poor	visual	prognosis	in	several	studies.7,17,19	Patient-related	factors	were	identified	as	one	common	reason	for	a	delay	in	diagnosis.	However,	syphilitic	uveitis	is	a	great	masquerader,	and	lack	of	recognition	was	identified	as	a	major	issue	in	delayed	diagnosis.	A	related	consideration	was	failure	to	order	serologic	testing	for	syphilis.			In	summary,	we	have	presented	a	description	of	practice	patterns	for	syphilitic	uveitis.	One	potential	limitation	of	our	work	relates	to	participation	bias,	since	Study	Group	members	came	from	one	professional	society,	albeit	the	largest	international	society	with	specific	interest	in	inflammatory	eye	disease.	Another	potential	limitation	stems	from	the	fact	that	the	field	is	rapidly	evolving	as	syphilis	re-emerges	and	new	
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management	approaches	are	applied.	For	example,	within	a	relatively	short	period,	more	members	may	embrace	PCR	testing	of	ocular	fluid,	as	is	being	applied	routinely	in	more	common	intraocular	infections.35	Despite	these	limitations,	our	work	presents	a	unique,	current	and	comprehensive	description	of	the	management	of	syphilitic	uveitis	by	a	large	and	international	group	of	ophthalmologists	who	specialize	in	the	treatment	of	inflammatory	eye	disease.	Arguably	our	most	important	observation	is	the	role	of	syphilis	serologic	testing	in	the	timely	diagnosis	of	syphilitic	uveitis.	Over	80%	of	Study	Group	members	test	any	patient	who	presents	with	uveitis	for	syphilis.	
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